PremiumCompany AnnouncementsAstraZeneca’s EMBOLD-Asia Trial Signals Fresh Push Into Obesity Market1d agoAZN
PremiumCompany AnnouncementsAstraZeneca’s SELENE 3 Trial Targets Extra Weight-Loss Upside for AZN Investors1d agoAZN